FDA Trims Broad Label for Biogen’s Alzheimer’s Drug Amidst Harsh Criticism
XTalks
JULY 12, 2021
The US Food and Drug Administration’s (FDA) recent approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab) was met with a lot of backlash, prompting the health agency to narrow its recommendation of the drug for mild forms of the disease. head of research and development at Biogen, in a statement from the company. This week, Rep.
98 
Let's personalize your content